Chronic Lymphocytic Leukemia Drug Treatment Shows Promise


Chronic Lymphocytic Leukemia Drug Treatment Shows Promise

An experimental drug, called ibrutinib, shows promise treating elderly patients withِ chronic lymphocytic leukemia, according toِ preliminary findings fromِ a phase I/II clinical trial.

Clinical trial results do not always hold up in later studies.

In theِ trials, theِ oral agent wasِ foundِ to haveِ “few side effects andِ a high one-year survival rate inِ older patients,” theِ researchers report.
Ibrutinib, alsoِ labeled PCI-32765, wasِ designed toِ target Bruton’s tyrosine kinase, a protein thatِ isِ essential forِ CLL-cell survival andِ proliferation.
Standard treatment forِ CLL involves useِ ofِ the chemotherapeutic drug fludarabine.

This story was provided by MyHealthNewsDaily, a sister site to LiveScience.

For theِ science geek inِ everyone, Live Science offers a fascinating window intoِ the natural andِ technological world, delivering comprehensive andِ compelling news andِ analysis onِ everythingِ from dinosaur discoveries, archaeological finds andِ amazing animals toِ health, innovation andِ wearable technology.
We aim toِ empower andِ inspire ourِ readers withِ theِ tools needed toِ understand theِ world andِ appreciate itsِ everyday awe..